125 related articles for article (PubMed ID: 29769011)
1. Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents.
Laribi K; Alani M; Truong C; de Materre AB
Recent Pat Anticancer Drug Discov; 2018; 13(3):308-340. PubMed ID: 29769011
[TBL] [Abstract][Full Text] [Related]
2. From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma.
Mihaila RG
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):283-295. PubMed ID: 28933264
[TBL] [Abstract][Full Text] [Related]
3. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
4. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Wilcox R; Naushad H; Rohr J; Heavican TB; Wang C; Bouska A; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):89-100. PubMed ID: 26319391
[TBL] [Abstract][Full Text] [Related]
5. New targets of therapy in T-cell lymphomas.
Erter J; Alinari L; Darabi K; Gurcan M; Garzon R; Marcucci G; Bechtel MA; Wong H; Porcu P
Curr Drug Targets; 2010 Apr; 11(4):482-93. PubMed ID: 20196721
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
[TBL] [Abstract][Full Text] [Related]
7. Targeting epigenetic regulators in the treatment of T-cell lymphoma.
Ahmed N; Feldman AL
Expert Rev Hematol; 2020 Feb; 13(2):127-139. PubMed ID: 31903826
[No Abstract] [Full Text] [Related]
8. Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
Klemke CD; Goerdt S
G Ital Dermatol Venereol; 2008 Dec; 143(6):365-74. PubMed ID: 19169209
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic agents for T-cell lymphomas.
Chan TS; Kwong YL; Tse E
Discov Med; 2013 Aug; 16(86):27-35. PubMed ID: 23911229
[TBL] [Abstract][Full Text] [Related]
11. Genetic Landscape and Classification of Peripheral T Cell Lymphomas.
Sandell RF; Boddicker RL; Feldman AL
Curr Oncol Rep; 2017 Apr; 19(4):28. PubMed ID: 28303495
[TBL] [Abstract][Full Text] [Related]
12. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
13. Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma.
Yoo HY; Kim P; Kim WS; Lee SH; Kim S; Kang SY; Jang HY; Lee JE; Kim J; Kim SJ; Ko YH; Lee S
Haematologica; 2016 Jun; 101(6):757-63. PubMed ID: 26819049
[TBL] [Abstract][Full Text] [Related]
14. T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases.
Coupland SE; Foss HD; Assaf C; Auw-Haedrich C; Anastassiou G; Anagnostopoulos I; Hummel M; Karesh JW; Lee WR; Stein H
Ophthalmology; 1999 Nov; 106(11):2109-20. PubMed ID: 10571346
[TBL] [Abstract][Full Text] [Related]
15. T-cell lymphoma forum.
Kwong YL
Expert Rev Anticancer Ther; 2010 Apr; 10(4):493-8. PubMed ID: 20397914
[TBL] [Abstract][Full Text] [Related]
16. The expression and prognostic significance of platelet-derived growth factor receptor alpha in mature T- and natural killer-cell lymphomas.
Chen YP; Chang KC; Su WC; Chen TY
Ann Hematol; 2008 Dec; 87(12):985-90. PubMed ID: 18633616
[TBL] [Abstract][Full Text] [Related]
17. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
18. Novel insights into the pathogenesis of T-cell lymphomas.
Van Arnam JS; Lim MS; Elenitoba-Johnson KSJ
Blood; 2018 May; 131(21):2320-2330. PubMed ID: 29666117
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
20. New drug therapies in peripheral T-cell lymphoma.
Howman RA; Prince HM
Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
